Brainomix's e-Lung Shows Clinical Utility in Phase III Trial for Lung Disease Assessment
ENTITYBrainomix's e-Lung AI tool has demonstrated clinical utility in Phase III trials for assessing lung disease progression and treatment response. The trial shows AI imaging tools are increasingly being incorporated into clinical study protocols, particularly for assessing disease progression in conditions like interstitial lung disease. The trial represents an important validation pathway for AI medical imaging devices—moving beyond regulatory clearance to demonstrate actual clinical benefit in prospective studies. This is significant given recent evidence that fewer than 1% of FDA-cleared AI devices have been tested for clinical benefit in peer-reviewed studies. The e-Lung deployment in clinical trials suggests that imaging AI tools may find earlier adoption in research settings than in routine clinical practice, where integration challenges and liability concerns remain higher. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.